It depends on the standard you follow. As of September 2026, TG Therapeutics, Inc. (TGTX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 9.37% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.04% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 9.37% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.34% / 33% · Receivables / Mkt Cap (36m) 5.24% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 9.37% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.34% / 33.33% · Receivables / Mkt Cap (24m) 5.24% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 42.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 29.4% / 33.33% · Receivables / Avg Assets (4Q) 26.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 46.8% / 33.33% · (Cash+ST Inv) / Total Assets 31.7% / 33.33% · (Cash+Recv) / Total Assets 57.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, TG Therapeutics, Inc. (TGTX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. TG Therapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
TG Therapeutics, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
TG Therapeutics, Inc. (NASDAQ: TGTX) is a Healthcare company (Biotechnology) with a market capitalization of $9.5B. The Maz Rating grades it against the other companies in its sector.
TG Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $62.76, TG Therapeutics, Inc. trades at 84.3x trailing earnings, 10.6x sales and 15.4x book value, with an EV/EBITDA of 51.3. Over the last twelve months it generated about $898M of revenue and $113M of net income. It runs a gross margin of 82.7%, an operating margin of 21.5% and a net margin of 11.8%. It shows return on equity of 17.6%, return on invested capital of 10.3% and a free cash flow yield of 0.9%. On the balance sheet: a debt-to-equity ratio of 1.32 and a current ratio of 4.50. Over the past 52 weeks the share price ranged from $26.76 to $68.03, with a beta of 1.81.
TG Therapeutics, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 11 Buy, 1 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.